Drug Trial Radar · NCT04995029
Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users
Last checked: Nov 20, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
785
Actual
Start
Oct 26, 2021
Primary completion
Jun 26, 2024
Study completion Jun 26, 2024
Sponsor
- Lead sponsor
- Indivior Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the induction phase of the study is to compare treatment retention of participants following rapid induction or standard of care (SoC) induction onto extended-release buprenorphine. The primary objective of the maintenance phase is to compare the efficacy of 100 mg and 300 mg maintenance doses of extended-release buprenorphine administered every 4 weeks.
Conditions
- Moderate to Severe Opioid-use Disorder
Interventions
Transmucosal BuprenorphineDrug
Transmucosal (TM) buprenorphine as selected by the Investigator per local prescribing guidelines, administered either under the tongue (sublingual) or between the gum and cheek (buccal)
Extended-release BuprenorphineDrug
Administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maintenance Phase: Percentage of Responders for Weekly Opioid Use Over Weeks 20 to 38Time frame: Weeks 20 to 38
- Induction Phase: Percentage of Participants Receiving Injection 2 at the Week 2 VisitTime frame: Week 2
Locations
29 sites in 2 countries. Site status is shown where the registry gives one.
Collaborative Neuroscience Network, LLC
Garden Grove, California
Asclepes Research Centers
Panorama City, California
Artemis Institute for Clinical Research
San Diego, California
Bay Pines VA Healthcare System
Bay Pines, Florida
Sarkis Clinical Trials
Gainesville, Florida
Accel Research Sites- Lakeland Clinical Research Unit
Lakeland, Florida
Behavioral Clinical Research, Inc
Miami Lakes, Florida
Innovative Clinical Research Inc.
North Miami, Florida
Clinical Neuroscience Solutions, Inc
Orlando, Florida
Brigham and Women's Hospital
Boston, Massachusetts
Hassman Research Institute
Berlin, New Jersey
Center For Emotional Fitness
Cherry Hill, New Jersey
ICAHN School of Medicine at Mount Sinai
New York, New York
Duke Hospital
Durham, North Carolina
Monroe Biomedical Research
Monroe, North Carolina
Midwest Clinical Research
Dayton, Ohio
Pahl Pharmaceutical Professionals LLC
Oklahoma City, Oklahoma
SP Research, PLLC
Oklahoma City, Oklahoma
Unity Clinical Research
Oklahoma City, Oklahoma
Today Clinical Research
Oklahoma City, Oklahoma
Clinical Research Associates of Central PA
Altoona, Pennsylvania
Carolina Medical Research, LLC
Clinton, South Carolina
Prisma Health ITOR Research Pharmacy
Greenville, South Carolina
Carolina Medical Research, LLC
Greenville, South Carolina
David Weitzman
Myrtle Beach, South Carolina
Insite Clinical Research
DeSoto, Texas
Progressive Clinical Research
Bountiful, Utah
Alpine Research Organization
Clinton, Utah
Centre for Addiction and Mental Health
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.